Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients...

Full description

Bibliographic Details
Main Authors: Shinji Ohtake, Takashi Kawahara, Ryo Kasahara, Hiroki Ito, Kimito Osaka, Yusuke Hattori, Jun-ichi Teranishi, Kazuhide Makiyama, Nobuhiko Mizuno, Susumu Umemoto, Yasuhide Miyoshi, Noboru Nakaigawa, Hiroshi Miyamoto, Masahiro Yao, Hiroji Uemura
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2016/9846823

Internet

http://dx.doi.org/10.1155/2016/9846823

Similar Items